Bruce Downey Sells 13,000 Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Stock

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Director Bruce Downey sold 13,000 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $14.51, for a total transaction of $188,630.00. Following the sale, the director now directly owns 41,234 shares in the company, valued at $598,305.34. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Shares of Momenta Pharmaceuticals stock traded down $0.56 during trading hours on Friday, hitting $13.85. The company had a trading volume of 419,530 shares, compared to its average volume of 654,181. Momenta Pharmaceuticals, Inc. has a twelve month low of $9.55 and a twelve month high of $32.20. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of -6.82 and a beta of 2.23.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its earnings results on Friday, February 22nd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.39. Momenta Pharmaceuticals had a negative net margin of 232.92% and a negative return on equity of 47.74%. The business had revenue of $42.80 million during the quarter, compared to analysts’ expectations of $17.11 million. During the same quarter in the prior year, the business posted $0.18 EPS. The company’s revenue for the quarter was down 33.7% on a year-over-year basis. Analysts expect that Momenta Pharmaceuticals, Inc. will post -1.72 earnings per share for the current year.

A number of equities research analysts have commented on MNTA shares. ValuEngine downgraded shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Stifel Nicolaus reissued a “buy” rating and issued a $29.00 price objective on shares of Momenta Pharmaceuticals in a research report on Friday, February 22nd. BidaskClub downgraded shares of Momenta Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, January 12th. Zacks Investment Research downgraded shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 5th. Finally, BTIG Research started coverage on shares of Momenta Pharmaceuticals in a research report on Monday, March 18th. They issued a “neutral” rating and a $14.15 price objective on the stock. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $22.03.

Several institutional investors have recently modified their holdings of MNTA. Wells Fargo & Company MN boosted its stake in Momenta Pharmaceuticals by 3.8% during the 3rd quarter. Wells Fargo & Company MN now owns 236,651 shares of the biotechnology company’s stock worth $6,224,000 after purchasing an additional 8,710 shares during the period. Bank of New York Mellon Corp boosted its stake in Momenta Pharmaceuticals by 3.2% during the 3rd quarter. Bank of New York Mellon Corp now owns 894,031 shares of the biotechnology company’s stock worth $23,513,000 after purchasing an additional 27,708 shares during the period. BlackRock Inc. boosted its stake in Momenta Pharmaceuticals by 3.4% during the 3rd quarter. BlackRock Inc. now owns 12,080,344 shares of the biotechnology company’s stock worth $317,713,000 after purchasing an additional 399,232 shares during the period. FMR LLC boosted its stake in Momenta Pharmaceuticals by 1.0% during the 3rd quarter. FMR LLC now owns 11,747,215 shares of the biotechnology company’s stock worth $308,951,000 after purchasing an additional 113,380 shares during the period. Finally, Trexquant Investment LP acquired a new stake in Momenta Pharmaceuticals during the 3rd quarter worth $483,000. Institutional investors and hedge funds own 96.88% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Bruce Downey Sells 13,000 Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Stock” was first reported by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/04/14/momenta-pharmaceuticals-inc-mnta-director-sells-188630-00-in-stock.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

Recommended Story: What is channel trading?

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.